- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | CARSGEN-B (02171): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS | - | HKEx | ||
| Di | CARSGEN-B (02171): NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED SHAREHOLDERS | 1 | HKEx | ||
| Di | CARSGEN-B (02171): REVISED FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING | 1 | HKEx | ||
| Di | CARSGEN-B (02171): SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| Di | CARSGEN-B (02171): SUPPLEMENTAL CIRCULAR - (I) RE-ELECTION OF THE RETIRING DIRECTOR, AND (II) SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING | 1 | HKEx | ||
| Di | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - ABSTRACTS FROM THE ONGOING STUDIES OF ZEVORCABTAGENE AUTOLEUCEL AND CT071 ARE TO BE PRESENTED AS AN ORAL PRESENTATION ... | 1 | HKEx | ||
| Mo | CARSGEN-B (02171): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| Mo | CARSGEN-B (02171): (1) RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR; (2) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR; AND (3) CHANGE IN THE ... | - | HKEx | ||
| Mo | CARsgen Therapeutics: CARsgen Submitted Responses to FDA Observations | 40 | PR Newswire | SHANGHAI, April 29, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies... ► Artikel lesen | |
| Mo | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - CMC RESPONSES TO FDA OBSERVATIONS SUBMITTED | 1 | HKEx | ||
| 18.04. | CARSGEN-B (02171): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS | - | HKEx | ||
| 18.04. | CARSGEN-B (02171): NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED SHAREHOLDERS | 1 | HKEx | ||
| 18.04. | CARSGEN-B (02171): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 18.04. | CARSGEN-B (02171): NOTICE OF ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 18.04. | CARSGEN-B (02171): PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES, RE-ELECTION OF RETIRING DIRECTORS, RE-APPOINTMENT OF AUDITOR, ... | 1 | HKEx | ||
| 18.04. | CARSGEN-B (02171): ANNUAL REPORT 2023 | 1 | HKEx | ||
| 11.04. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - ORAL PRESENTATION OF RESEARCH UPDATES ON SATRICABTAGENE AUTOLEUCEL AT 2024 ASCO ANNUAL MEETING | - | HKEx | ||
| 27.03. | CARsgen Therapeutics: CARsgen Announced 2023 Annual Results | 118 | PR Newswire | SHANGHAI, March 27, 2024 /PRNewswire/ -- March 27, 2024, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic... ► Artikel lesen | |
| 26.03. | CARSGEN-B (02171): PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND THE ADOPTION OF THE EIGHTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION | - | HKEx | ||
| 26.03. | CARSGEN-B (02171): ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023 | 1 | HKEx |
Seite:
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SPRINGWORKS THERAPEUTICS | 46,840 | +0,32 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | ||
| AVIDITY BIOSCIENCES | 25,800 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, April 22, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide... ► Artikel lesen | |
| KEROS THERAPEUTICS | 57,72 | 0,00 % | Prozessmanagement in der Gemeinschaftsverpflegung / Keros Consult optimiert Warenwirtschaft für Eichhof-Stiftung Lauterbach | Düsseldorf (ots) - Ab sofort unterstützt Keros Consult, eine hundertprozentige Tochtergesellschaft der Klüh-Gruppe, die Eichhof-Stiftung Lauterbach bei der Optimierung ihrer Bestell- und Produktionsprozesse... ► Artikel lesen | |
| IMMUNOVANT | 28,520 | 0,00 % | Should You Hold Immunovant (IMVT)? | ||
| ARVINAS | 32,480 | +2,23 % | Arvinas Inc.: Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer | NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 36,240 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting | New preclinical data on novel E3 pairing and structural mechanisms for KT-333, a First-in-Class STAT3 degrader, presented in AACR's late-breaking poster session Nello Mainolfi, Founder, President... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,740 | +2,45 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
| JANUX THERAPEUTICS | 58,19 | 0,00 % | Janux Therapeutics jumps as much as 28% on heels of Deciphera buyout deal | ||
| VERA THERAPEUTICS | 42,310 | +7,09 % | Aktien New York Ausblick: Vor dem Start in die Berichtssaison stabil erwartet | NEW YORK (dpa-AFX) - Nach einem schwachen Handelsverlauf am Vortag dürften sich die US-Börsen am Donnerstag stabilisieren. Am Mittwoch hatte eine überraschend hohe Inflation im Monat März die Hoffnungen... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,340 | 0,00 % | Recursion Pharmaceuticals: Recursion to Participate in Upcoming Investor Conferences | ||
| COGENT BIOSCIENCES | 6,910 | +6,31 % | Cogent Biosciences, Inc.: Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor | WALTHAM, Mass. and BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| CULLINAN THERAPEUTICS | 28,100 | +4,04 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer | CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment... ► Artikel lesen | |
| CABALETTA BIO | 12,410 | 0,00 % | Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - First patient dosed with CABA-201 in the RESET (REstoring SElf-Tolerance) clinical trial program - - Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials... ► Artikel lesen | |
| DYNE THERAPEUTICS | 25,830 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer | WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for... ► Artikel lesen | |
| NUVALENT | 70,65 | +2,57 % | Nuvalent, Inc.: Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 | Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile
Zidesamtinib shown to... ► Artikel lesen |
Das Unternehmen CARSGEN THERAPEUTICS HOLDINGS LTD kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
